However, being very effective in non-small cell lung cancer (NSCLC) patients and cell lines with MET amplification, marked MET overexpression or MET exon 14 skipping mutations and HGF-mediated activation of MET signaling, the low response of melanoma cell lines to capmatinib is in line with results of a recent study [4]. Here, MET is linked to non-small cell lung carcinoma.